NewsMarkets

Health

Novo Nordisk's Wegovy Lowers BMI in Children as Young as 6

The STEP Young trial shows the drug significantly reduces body mass index in children aged 6 to 11, expanding treatment options beyond the current age limit of 12.

4 publishers · 4 articles · first seen 16 Nov 2026 · updated 5h ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

The story so far

4 publishers have covered this in 4 articles since 16 Nov 2026. CNBC published first, on 16 November at 15:00 UTC; News Feed followed 0 min later. The most recent article, from MedPageToday.com - medical news for physicians, appeared on 16 November at 21:47 UTC.

Outlets reporting it: CNBC (major outlet), News Feed (major outlet), Quartz, MedPageToday.com - medical news for physicians.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. Six-year-olds. Novo’s new frontier for weight-loss drugs News Feed ·
  2. Novo says Wegovy injection lowers BMI and obesity rates in children in trial CNBC ·
  3. Wegovy Reduces BMI in Kids With Obesity as Young as 6 MedPageToday.com - medical news for physicians
  4. Novo Nordisk's weight loss injection cut obesity in young children, trial shows Quartz

In this story

  • Novo Nordisk
  • Wegovy
  • STEP Young trial
Embed this story

Paste this into any web page to show the live odds, with a link back here.